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ABSTRACT
Objective : Effect of SCIT in allergic rhinitis patients sensitive to multiple
allergens.
Methods : In this study symptom score medication score of 30 allergic
rhinitis patient’s were collected. Intradermal skin test, Absolute Eosinophil
Count and FEV1% were performed at baseline and 12 months after treatment
with subcutaneous Immunotherapy.
Result: There is significant improvement in Nasal symptoms and Non-Nasal
symptoms. There is better improvement in nasal symptoms compared to non
nasal symptoms. Subcutaneous immunotherapy reduces medication
requirement. Skin sensitivity reactions have reduced. Patients showed
significant symptomatic improvement even when skin sensitivity reactions
were present.  Immunotherapy lowers total IgE and absolute eosinophil
count.
Conclusion : SCIT demonstrated clinical improvement in Allergic rhinitis/
Asthma, sensitive to multiple allergen.
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1INTRODUCTION
Allergic diseases are common and they have increased in
frequency over the last few decades. More than 3O% of the population
suffer from allergic diseases. The nose is the site of most allergic
symptoms and illnesses than  any other organ due to its effective
filtering action for allergen.
The term allergy was coined by Clemiers Von Pirquet in1906.
Rhinitis is defined by a combination of two or more nasal symptoms:
Running nose, nasal obstruction, itching and sneezing. Allergic rhinitis
occurs when these symptoms are the result of IgE mediated
inflammation following exposure to allergens.
Management  involves  allergen avoidance, use of antihistamines,
topical steroids and allergen immunotherapy Immunotherapy involves
the step-wise incremental injection of increasing subcutaneous doses of
allergen, in order to suppress symptoms on subsequent re-exposure to
that allergen. In contrast to topical corticosteroids, immunotherapy,
when given monthly for three to four years, has been shown to induce
long-term remission for at least three years following discontinuation of
treatment.  Studies strongly suggest that immunotherapy is the only
treatment that has the potential to modify the course of allergic disease.
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AIMS AND OBJECTIVE 
To evaluate the effect of immunotherapy for 
1. Reduction of symptoms during allergic rhinitis 
2. Reduction of medication requirements  
3. Alteration of immunological markers-  IgEs, absolute eosinophil 
count. 
4. Alteration in pulmonary function test  
 
 
 
 
 
 
 
 
 
3REVIEW OF LITERATURE
ANATOMY OF NOSE
The Vestibule, a skin lined area bearing coarse hairs and vibrissae
is a dilated passageway leading from external nares to nasal cavity and
limited superiorly by limen nasi.
Pyriform aperture is a pyramidal shaped opening bound by nasal
bones superiorly and inferolaterally by maxilla. Anterior nasal spine lies
inferiorly. All nasal cartilages are hyaline cartilage. Cartilaginous
framework of external nose is formed by upper lateral and lower lateral
or alar cartilages. The lower lateral cartilage gives rise to medial and
lateral crus which forms the dome of nasal tip. Dorsal branch of
ophthalmic artery and infra orbital branch of maxillary artery supplies
dorsum and lateral wall of external nose.
Venous network- Frontomedian area drains into facial vein while
the orbitopalpebral area drains to ophthalmic vein. Supratrochlear and
supraorbital veins join to form angular vein at the inner canthus and
continues as facial vein.
The skin of external nose is supplied by ophthalmic and maxillary
branch of trigeminal nerve. Lymphatic drainage terminates into
submandibular and submental nodes
4NASAL CAVITY
Nasal cavity extends from external nares to posterior choana and
continues as nasopharynx. It extends vertically from palate to cribriform
plate. Superiorly cavity narrows down to form the olfactory cleft. Floor
is formed by horizontal process of palatine bone and palatine process of
maxilla. Terminal branches of nasopalatine nerve, greater palatine artery
and stensons organ enters the nasal cavity through incisive canal which
lies about 12 mm behind the end of floor.
Roof is divided into frontonasal, ethmoidal and sphenoidal  parts.
Frontonasal and sphenoidal parts of roof slopes downwards while
ethmoidal part is almost in the horizontal plane. Olfactory epithelium
lines  the roof and upper third of medial and lateral walls of nasal cavity.
Respiratory epithelium lines the remaining part of nasal cavity and
continuous with paranasal sinuses, nasolacrimal duct and nasopharynx.
NASAL SEPTUM
Septum is composed of membranous, cartilaginous and bony
parts. Quadrilateral cartilage forms the major bulk of septum while
upper and lower lateral alar cartilages provides a minimal contribution
to the formation of septum.
5The bony part of septum is formed  by vomer and perpendicular
plate of ethmoid  . Perpendicular plate forms the anterosuperior part of
bony septum. It continues with the cribriform plate and crista galli.
Vomer forms the posteroinferior bony nasal septum and articulates with
the rostrum of sphenoid, palatine and maxillary crests, perpendicular
plate above and quadrilateral cartilage below. Posteriorly it forms the
posterior free border of septum.
HISTOLOGY
The nasal cavity is predominantly lined by respiratory epithelium
composed of either ciliated or non ciliated pseudostratified columnar
epithelium. A small area in the roof is lined by olfactory epithelium. The
columnar cells bears 300-400 microvilli which aids in increasing the
surface area and prevent drying.
The Olfactory epithelium spreads from cribriform plate to upper
septum. It is composed of receptor cells, supporting cells and brain stem
cells. The brain stem cells is responsible for regenerative capacity of
olfactory epihelium.
6BLOOD SUPPLY
The rich blood supply of septum is contributed by both the
internal and external carotid arteries.  Septum is supplied  by
sphenopalatine artery posteroinferiorly, greater palatine artery
anteroinferiorly, superior labial branches of facial artery anteriorly and
anterior and posterior ethmoidal arteries superiorly.
NERVE SUPPLY
Major part of  sensory supply of nasal septum is by maxillary
division of trigeminal nerve.  Anterosuperior part of nasal septum is
supplied by  anterior ethmoidal nerve while anteroinferior part is
supplied by anterior superior alveolar nerve. Posteroinferior  septum
receives a small supply from nerve to pterygoid canal and anterior
palatine nerve branches.
Sensory nerves are accompanied by postganglionic sympathetic
fibers and parasympathetic secretomotor fibers.
LATERAL NASAL WALL
INFERIOR MEATUS- it’s the largest meatus and forms part of lateral
wall of nose. It lies lateral to inferior turbinate and extends almost along
the whole length of nasal cavity. The opening of nasolacrimal duct is
7seen anterior to the junction of anterior and middle third of inferior
meatus.  Hasner’s valve, a mucosal fold covers the opening of the duct.
INFERIOR TURBINATE- it is formed by an independent bone. The
bone has an irregular surface grooved by vascular channels and
mucoperiosteum is firmly attached to the same. The maxillary process
of inferior concha articulates with inferior margin of maxillary hiatus.
The other bony articulations are formed by palatine bone, ethmoid and
lacrimal bones. It forms the medial wall of nasolacrimal duct. It has an
extensive submucosal cavernous plexus under autonomic control. This
provides the major contribution to nasal resistance. The respiratory
epithelium lining the inferior turbinate is rich in goblet cells which
decrease in density from anterior to posterior.
MIDDLE MEATUS- it is the part of lateral nasal wall lying lateral to
middle turbinate. The frontal, maxillary and anterior ethmoidal sinuses
drain into middle meatus. The maxillary ostium is bounded posteriorly
by perpendicular plate of palatine bone, inferiorly by maxillary process
of inferior turbinate bone, superiorly by uncinate and bulla and lastly
anterosuperiorly by lacrimal bone.  The anterior and posterior fontanelle
is the membranous portion seen anterior and posterior to uncinate.
8Accessory ostium, may be formed as a result of infection, usually is
seen in the posterior fontanelle.
The uncinate is a thin crescent shaped bone with concavity
posteriorly running parallel to the anterior face of ethmoidal bulla.
Anteriorly it’s attached to maxillary hiatus. Superiorly it may attach to
skull base or may fuse with the insertion of middle turbinate. In these
two situations, both frontal and maxillary sinuses drain into ethmoidal
infundibulum with obvious pathological consequences. Sometimes
uncinate may insert laterally to lamina papyracea such that the
ethmoidal infundibulum ends as a blind pouch known as terminal
recess.
The aggernasi is a small mound lying anterior to middle turbinate
on the lateral wall of nose. It may be pneumatised in 5 to 80 %
population. Hiatus semilunaris is a 2 dimensional space between the
anterior surface of ethmoidal bulla and posterior free border of uncinate.
It is also known as inferior hiatus semilunaris coined by Grunwald.
Superior hiatus semilunaris lies between the basal lamella of middle
turbinate and ethmoidal bulla. This sickle shaped cleft leads into
retrobullar recess.
9Ethmoidal infundibulum is a 3 dimensional funnel shaped space
connecting maxillaryostium to middle meatus via hiatus semilunaris.
Uncinate and hiatus semilunaris forms the medial boundary of this
space. The anterior face of bulla lies posteriorly and lamina papyracea
lies laterally. Superior boundary depends on the attachment of uncinate
process.
Ethmoidal bulla is the most constant aircell .It is the largest
ethmoidal air cell. A poorly pneumatised or completely unpneumatised
bulla known as torus lateralis is seen in 8 % of population.  Anterior
face of bulla forms the posterior margin of ethmoidal infundibulum and
hiatus semilunaris. The posterior face may fuse with the basal lamella of
middle turbinate. If it does not fuse with middle turbinate, it forms a
retrobullar recess known as lateral sinus or recessus supraethmoidalis.
Superiorly it forms the posterior wall of frontal recess when it reaches
the roof of ethmoid.
Anatomical variations such as concha bullosa, paradoxical middle
turbinate, enlarged ethmoidal bulla, haller cells, septal deflection,
medialised uncinate process  etc., contributes to the pathogenesis of
sinusitis.
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SUPERIOR TURBINATE- is seen above the superior meatus.
Posterior ethmoidal cell opens into superior meatus. Spenoid sinus
opens into spenoethmoidal recess which lies medial to superior
turbinate.
HISTOLOGY OF LATERAL WALL
Respiratory epithelium composed of ciliated columnar epithelium
lines majority of the lateral wall of nose. A small portion over the
superior turbinate is lined by olfactory epithelium.  Areas of squamous
metaplasia is seen in anterior inferior turbinate as it is subject to greatest
air flow.
BLOOD SUPPLY OF LATERAL WALL
The external and internal carotid artery branches supply the
lateral wall of nose. Sphenopalatine artery enters the nose through
sphenopalatine foramen and supplies all turbinates and meatus
Sphenopalatine foramen lies inferior to the horizontal attachment of
middle turbinate.
Excessive enlargement of middle meatal antrostomy may damage
the sphenopalatine artery. The anterior part of lateral wall of nose is
supplied by  facial artery branches. Greater palatine artery  supplies the
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lateral wall of nose adjacent to palate. Anterior and posterior ethmoidal
arteries supplies superior lateral wall.
Venous drainage is carried through facial and ophthalmic vessels
to sphenopalatine vein. Intracranially via ethmoidal veins to veins of
dura and also to superior sagittal sinus via foramen caecum.
NERVE SUPPLY OF LATERAL WALL
The anterosuperior part is supplied by anterior ethmoidal nerves.
Posteriorly  by branches of pterygopalatine ganglion and anterior
palatine nerves. Infraorbital nerve, a branch of maxillary nerve supplies
a small area anteriorly. The anterior inferior meatal region is supplied by
anterior superior alveolar nerves .
LYMPHATIC DRAINAGE
Anteriorly drains into submandibular node and posteriorly to
lateral pharyngeal, retropharyngeal and upper deep cervical nodes.
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NASAL AIRWAY  AND FACTORS INFLUENCING NASAL
RESISTANCE TO AIRFLOW
Nose contributes to two thirds of total airway resistance in adults.
Nasal resistance is divided into three compartments. They are turbinated
nasal passage, nasal valve and nasal vestibule.
Nasal vestibule acts as a flow limiting area as its walls are
compliant and easily collapsible under the influence of negative
pressure generated during inspiration.
Nasal valve is the narrowest part of nose and it is an important
determining factor of nasal resistance to airflow. It is formed by the
inferior edge of upper lateral cartilage, anterior end of inferior turbinate
along with adjacent part of nasal septum.
The degree of engorgement of venous erectile tissue is one of the
major determining factor for nasal resistance. Accessory respiratory
muscles also influence nasal resistance by maintaining the patency of
nostril during inspiration. Sympathetic  autonomic nervous system plays
a major role in regulating nasal resistance.
Airflow through nasal passage is inversely related to nasal
resistance. The oscillations in nasal resistance are referred to as the nasal
cycle. Hence airflow through nasal passage is essentially asymmetrical.
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IMMUNOLOGY
Immunology was initially a study of response of animal to
infection.  Now it involves the study of allergy, immunochemistry,
immunopathology, clinical immunology, tumor immunology and
transplantation.
Allergy is a type of hypersensitivity reactions with harmful
immune response resulting in tissue injury and serious diseases.  Type I
is an Ig E mediated hypersensitivity reaction due to allergen mediated
crosslinking of preformed Ig E antibody bound to FC receptors on mast
cells.
IMMUNE SYSTEM
The main role of immune system comprising of lymphocytes and
antibodies is to distinguish between macromolecules that are indigenous
or foreign. The specificity is the ability of immune system to produce
specific antibody directed against non-self macro molecules which acts
as an antigen and stimulates immunity.
B and T Cells- naïve cells are lymphocytes which have not yet
been exposed to any antigen. On stimulation of these naïve B cells by
antigen, they are converted into plasma cells which synthesize antibody.
14
This is known as humoral immune response. Naïve T lymphocytes on
stimulation by antigens transform to activated T cells which secrete
proteins, cytokines. This type of immune response is termed cell
mediated  immune response. T helper cells, cytokines and their signal
proteins control entire immune responses. IgE synthesis, recruitment
and activation of inflammatory cells in IgE mediated reactions is under
the influence of T helper cells. Effector cells or cytotoxic T cells destroy
antigen containing cells by release of  cytokines or by direct contact.
The term hypersensitivity refers to an exaggerated response due
to an reaction between antigen and antibody or sensitized lymphocytes
leading to morbidity.
CLASSIFICATION OF HYPERSENSITIVY REACTIONS
TYPE NOMENCLATURE TIME
FRAME
MEDIATOR
I Immediate Minutes IgE
II Cytotoxic Minutes to
days
Ag- Ab
complex
III Immune complex Hours IgG,
complement,
IgM
IV Cell mediated Days T cells
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TYPE I HYPERSENSITIVITY
Mast cells coated with IgE antibody, when comes in contact with
allergen degranulates with the release of histamine and chemical
mediators. This is known as type I hypersensitivity reaction. Immediate
symptoms occur within minutes due to release of vasoactive amines.
Late phase response occurs 4 to 6 hours later. Late phase response
occurs by action of inflammatory cells that migrates into the involved
area  under the influence of cytokines released from mast cells and T
cells.
ANTIGEN PRESENTING CELLS
An antigen presented by an antigen presenting cell alone can be
recognized by T lymphocytes. Some common antigen presenting cells
are macrophages and langherhan’s cells.  Langerhan’s cells pick up
antigen proteins and break them into small peptide fragments which are
recognized by T lymphocytes . They travel to regional lymph nodes and
activate T cells. The first step In immune response is handling of
antigens by antigen  presenting cells. The next steps is stimulation of T
lymphocytes and requires specific antigen recognition. This is effected
by specific protein molecules in cell membranes known as cell receptors
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through which cell communicates with the environment. Cell receptor
has specificity for its ligand which is also a protein molecule.
CYTOKINES
These are soluble protein molecules synthesized by one cell and
alter the properties of another cell. Cytokines are signal proteins that
co-ordinates the activities of different cells and thus help in proper
functioning of immune system.  They collaborate together to form a
cytokine network which forms the basis of immune response and
inflammation. It act as a chemotactic factor and hemopoietic growth
factor. They have proinflammatory and cytotoxic effect.  Interleukin 3
stimulates the growth of precursors of basophils, eosinophils and mast
cells. IL 4 acts on B lymphocytes and stimulate the production of IgE.
IL 5 acts as an eosinophilic growth factor. IL 5 is responsible for
eosinophilia in allergic diseases. Cytokines in allergic diseases are
produced by Th 2 subset of T lymphocytes, mast cells and by other cell
types.  Th  1  and  Th2  are  the  two  type  of  T  helper  cells.  Th1  cells  are
stimulated mainly by microbial antigens while Th 2 cells are preferably
stimulated by allergens.  IL2 ,TNF and  gammainterferon secreted
byTh1  cells.   Th  2  cells  synthesize   IL  4,  IL  5,  IL  6and  IL  10,  IL  13.
GM- CSF and IL 13 are produced by both Th 1 and Th 2 cells. Th 0

17
cells are obligatory precursors of both Th 1 and Th 2 cells, hence they
produce cytokines similar to both type of cells. Th 1 activate
macrophages and support delayed type hypersensitivity.
Immunoglobulin isotype switching to IgG2a is also mediated by Th1
cells. On the other hand switching of Ig to IgG1 and IgE isotype is by
Th 2 cells. Thus Th2 cells provide efficient help for B cell activations.
Differentiation of naïve CD 4 T cells into specific Th subsets depends
on dose of antigen, major histocompatibility complex class 1 haplotype
and type of antigen presenting cells. Th1 cytokines predominantly
causes delayed hypersensitivity and Ig G synthesis while Th2 cytokines
induce Ig E synthesis and eosiniophilia. Interstingly these two cytokine
systems mutually suppress each other.
IgE
Ig E is secreted by B lymphocytes and plasma cells in respiratory
tract, gastrointestinal tract and regional lymph nodes.  It contributes to
less than 0.001 % of circulating immunoglobulins.
The initial formation of Ig E antibodies requires signals from Th 2
lymphocytes and IL 4. However the gamma interferons secreted by Th 1
cells antagonize the production of Ig E antibodies. Hence the ratio
between activated Th 2 and Th 1 cells is important in the regulation of
18
Ig E synthesis.  Mast cells have greater  affinity receptors for Ig
E(FcR1), thus contributing to the skin sensitizing ability of Ig E. As T
cells, eosinophils and antigen presenting cells have low affinity
receptors ( FcR2), their role in allergic reaction is uncertain.
IgE is a heat labile molecule and has a molecular weight of
188000. It is composed of  two heavy chains and two light chains
MAST CELLLS AND BASOPHILS
Both cells have greater affinity receptors for Ig E. As they
synthesize and release histamine and chemical mediators, they are the
primary cells of IgE mediated allergy.
Mast cells are seen predominantly in skin, respiratory tract and
gastrointestinal tract. They contain granules bearing histamine,
prostaglandins and leukotrienes. There are two types of mast cells.
Connective tissue mast cells are mast cells containing tryptase and
chynase ( MCTC). Another subgroup of mast cells known as mucosal
mast cells contain only tryptase and are referred to as MCT. When
connective tissue mast cells predominate in skin, it’s the mucosal mast
cells which migrate into nasal and bronchial epithelium and participate
in allergic reaction.
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IL 5 is an important growth and differentiation factor for
basophils. Basophils are circulating mast cells and mediate systemic
allergic reactions.
Degranulation and activation of mast cells is mediated by
interaction of allergen with Ig E antibody bound to FcR1 receptors. Non
immunological factors like mechanical trauma, thermal trauma, drugs,
some cytokines, radio contrast agents etc., also cause degranulation and
mediator release.
EOSINOPHIL
They are most important factor mediating allergic inflammation.
It contains bright red granules made up of eosinophil specific proteins
name major basic protein and eosinophilic cationic proteins which are
cytotoxic.  Cytokine growth factors, GM CSF, IL 3, IL 5 which are
produced by Th 2 cells influence the formation of eosinophils in bone
marrow. After circulating in blood for few days, it leaves the circulation
in response to adhesion molecules expressed over inflamed tissues.
Adhesion molecules  are grouped into selectins and integrins. The
selectin immunoglobulin super family contains ICAM-1 & VCAM-1.
These molecules are present on leukocytes and endothelial cell surface.
They are responsible for cell to cell contact by making the cells stick to
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each other through the interaction between adhesion molecule and its
ligand. These molecules are upregulated by the release of cytokines in
the inflamed area. The freely circulating eosinophils attach to
endothelial cells through these molecules, migrates between the cells
towards chemotactic factors. Eosinophils become activated in the
inflamed tissue and release cytotoxic proteins, leukotriene C4,
prostaglandin E2 and platelet activating factor. During allergic
inflammation, the survival of eosinophils is prolonged. Allergic
provocation test is used for studying allergic inflammation. It results in
an early and late response.
The early response starts within minutes and resolve within an
hour.  This occurs due to mast cell degranulation. This early response is
characterized by itching, wheel and flare reactions due to histamine
release. Histamine release in nose is characterized by sneezing, watery
rhinorrhea and nasal blockage. Late response usually develops after 4 to
6 hours. This is due to accumulation and activation of eosinophils, Th 2
cells and other cell and its inflammatory proteins namely cytokines,
mediator and cytotoxic  protein.
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ALLERGIC RHINITIS
Atopy refers to a predisposition to develop exaggerated
immunoglobulin E (IgE)-antibody responses against common inhaled
aeroallergens. Atopy is defined clinically as a positive skin prick test
and/or elevated serum allergen-specific IgE. The term 'allergy' refers to
the clinical expression of atopic allergic disease such as allergic rhinitis,
allergic bronchial asthma, atopic eczema and IgE-mediated food allergy.
Allergic rhinitis is a global health problem and is increasing in
prevalence. It is an Ig E mediated inflammation of nasal mucosa caused
by allergen. It presents with 3 cardinal symptoms of sneezing, nasal
discharge and nasal obstruction. Now a global health problem with
impact on school, work and social life.
Allergic rhinitis has been classified as intermittent allergic rhinitis
(IAR) and persistent  allergic rhinitis[PER] as per the ARIA document.
However seasonal and perennial rhinitis as per the conventional
classification cannot be used interchangeable with the IAR and PER .
To categorize a patient as PER, he should be symptomatic for atleast
more than 4 consecutive days in a week.
Based on symptoms and quality of life allergic rhinitis is graded
as mild, moderate or severe. In mild allergic rhinitis, symptoms are
22
present but not troublesome. There is no sleep disturbance or any
impairment of school work or daily activities. In moderate or severe
cases, symptoms are troublesome. Sleep is disturbed, daily activities are
impaired and school /work is impaired.
Rhinitis is the inflammation of nasal mucosal lining characterized
by nasal symptoms of rhinorrhea, sneezing, nasal blockage with or
without itching. Post nasal drip occurs with profuse anterior rhinorrhea
in allergic rhinitis cases. Sleep, school and work are adversely affected
by allergic rhinitis. Symptoms may revert spontaneously or on
treatment. Sinusitis does not exist without rhinitis as paranasal sinus
mucosa is in continuous with nasal mucosa and any nasal mucosal
congestion causes ostial congestion which eventually results in sinusitis.
Asthma and rhinitis are so interrelated that while 80% of astmatics have
rhinitis, about 40 % of rhinitis patients will eventually develop asthma.
The two important objective tests for the diagnosis of IgE
mediated allergy are Skin prick tests and allergen specific IgE.
SAPALDIA  conducted a randomized study to compare the diagnostic
efficiency of   skin prick tests and IGE. Positive predictive value of skin
prick test and total serum IgE were about 48.7 %  and 31.6%
respectively.
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OTHER CAUSES OF RHINITIS
Drug Induced Rhinitis -Non steroidal anti inflammatory drugs
like aspirin, diclofenac, ibuprofen, mefenamic acid etc commonly
induce rhinitis and asthma. They inhibit cyclooxygenase enzyme and
precipitate asthma.
Work Related Rhinitis.
Rhinitis Medicamentosa -Chronic use of intranasal
vasoconstrictors results in rebound nasal obstruction.
Hormonal Rhinitis
Rhinitis related to Physical and Chemical factors
Rhinitis in smokers  -Tobacco smoke  alter the mucociliary
clearance.
NARES[Nonallergic rhinitis with eosinophilia syndrome ]  - It is
characterized by the presence of nasal eosinophilia, absence of
demonstrable allergy, sneezing, rhinorrhea, itchinig and  hyposmia. It
occurs in children and adults. It responds usually to intranasal
glucocorticosteroids.
Senile Rhinitis
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Emotion  -Due to autonomic stimulation as in stress and sexual
arousal rhinitis has been seen.
Rhinosinusitis  -In acute viral rhinosinusitis or common cold
symptoms last for less than 10 days.
RISK FACTORS FOR ALLERGIC RHINITIS
GENETIC FACTORS
The best established risk factor for allergic rhinitis is a family
history of  allergy, especially of allergic rhinitis. there are several genes
which appear to be involved in atopy. These include 5q chromosome,
where genes exist for interleukin - 4 and IL-13, with markers associated
with the presence of a high level of serum IgE. Other possible
susceptibility loci exist on chromosome 11q, 13, 12q.
ENVIRONMENTAL FACTORS
Factors  such as lifestyle changes, increased exposure to allergen,
pollution and irritants, dietary modifications are responsible for
diminution of  protective nutrients, decrease in infections, leading to
reduction in Th1- type immune response (hygiene hypothesis) .Pollution
and diesel exhaust particles may induce a Th2-like inflammation.
25
ALLERGENS
Allergens are antigens that induce specific IgE antibodies and
react with the same. They are proteins or glycoproteins and rarely
glycans.
INHALANT ALLERGENS
Inhalant allergens are of two types- outdoor and indoor allergens.
The common  indoor allergens are house dust mites, pet animals, insects
and plant origin.  Outdoor  allergens are pollens and molds or
occupational agents. Association of greater risk with outdoor allergens
is  seasonal rhinitis, Indoor allergens is asthma and perennial rhinitis.
HOUSE DUST MITES.
The most important species are D.Pteronyssinus,
Dermatophagoides farinae, Euroglyphusmaynei, Lepidoglyphus
destructor and Blomia tropicalis.  It may potentiate a Th2 cell response.
They are  abundant in mattresses, pillows, bed bases, carpets,  fluffy
toys, fecal pellets. For sensitizing an infant 100 mites per gram of house
dust is sufficient . It is equivalent to 2 micrograms of Der p in 1 gram of
dust. The sensitized patients are more prone for  developing asthma .
ALLERGENS
26
POLLENS
Two types namely anemophilous and entomophilous pollens. The
anemophilous pollen are in aerodynamic form .The entomophilous
pollens are carried by insects.  The pollens causing the common
allergies are grasses, weed and trees.
FUNGAL ALLERGENS
Molds and yeast are plants which liberate allergenic spores in
large quantities into indoor and outdoor environments. Fungi and molds
are present in hot and humid conditions. As  mold spores are small in
size, they can penetrate deeply into the respiratory tract and can provoke
rhinitis and asthma.  Three important types of mold and yeast are
outdoor molds, indoor molds and molds present over food. The
atmospheric outdoor molds are Cladosporium, Alternaria, Aspergillus
and Penicillium.
Domestic indoor molds are present in the home . They grow in
aeration, climatization ducts, and in water pipes. They are abundant in
bathrooms and kitchens. .Molds that are present in foods are
Penicillium, Aspergillus and Fusarium
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INSECTS
Cockroach allergen- it is found in gastrointestinal secretions and
on its chitin shell. As the allergen is distributed in large particles, they
do not become airborne. They are mostly seen in high-rise apartments,
urban settings, and households with low income. Allergies to
cockroaches are more frequent in tropical areas such as South East Asia
FOOD ALLERGENS
Food allergy is rare in allergic rhinitis. Most common food
allergens  are cow’s milk , soya, peanuts, fish, eggs, milk, soyabeans,
and fruits like apples and peaches.
Automobile Pollutants that are associated with allergic rhinitis
are-
1) OXIDANT POLLUTANTS are carbon monoxide, nitric oxide,
volatile organic compounds.
2) SULPHUR POLLUTANTS- sulphur dioxide.
3) ORGANIC CHEMICAL AGENTS- polyaromatic hydrocarbons
like benzopyrene, benzofluoranthene, benzoanthracene,
benzofluoranthene and benzopirylene.
4) CARBON DIOXIDE
5) METALS
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DIAGNOSIS OF ALLERGIC RHINITIS
The diagnosis of allergic rhinitis is made by history of allergic
symptoms and diagnostic tests.
SYMPTOMS
Two or more of the following symptoms lasting for more than
one hour on most days :
Sneezing, Watery rhinorrhea, Nasal pruritis, Nasal obstruction-
usually bilateral, Conjunctivitis- ocular symptoms are more common in
pollen induced rhinitis
Other symptoms & signs:
Hyposmia or anosmia, Snoring, sleep problems, Postnasal drip or
chronic cough.
Diagnostic tests
skin tests -  by demonstration of allergen-specific IgE in the skin
blood       -  allergen specific IgE
Denniemorgan fold                            allergic salute
allergen vaccine vial Intradermal skin tests
positive and negative control Intradermal skin test
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SKIN TESTS
Immediate-hypersensitivity skin tests are used to demonstrate IgE
mediated allergic reaction. They are major diagnostic tools in the field
of allergy. They give confirmatory evidence for a diagnosis of specific
allergy.
Scratch Tests- done by making multiple cuts and apply a drop of
antigen. It is simple and quick procedure but of historical interest only.
Skin Prick Tests-
Modified skin prick test was introduced by Pepys. A drop of
glycerinated allergen extract is placed on the volar surface of forearm.
Skin is pricked through the drop using a lancet needle. Positive reaction
is measured by wheal and flare reaction.
Intradermal Skin Tests – are done by Injection of diluted liquid
allergen into the dermal layer of skin on the volar surface of forearm
using a mantoux syringe. 4 mm intra cutaneous wheal is created. The
wheal is remeasured within 10 to 20 minutes. Induration of 3 mm more
than control is considered as positive.
The positive control intradermal test is done by administration of
0.004 mg/ml of histamine to create a 4mm wheal which after 10 minutes
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increase to 7 mm or more. If this test fails to produce a positive
response, then false negative responses should be expected.
Negative control tests is done using Phenolated saline or human
serum albumin. This is injected to create a 4 mm wheal and it should not
enlarge more than 5 mm after 10 minutes.
PATCH TESTS
It is difficult to differentiate between allergic reactions and
irritative reactions.
IN VITRO TESTS
Serum-total IgE is measured by radioimmunoassay or enzyme
immunoassay. In adults, levels of 100–150 KU/l are normal.
Serum-specific IgE is considered to be positive when more than
0.35 KU/l. measurement of serum specific IgE is less sensitive than skin
tests.
Nasal challenge test
They are used for research purpose. It is not useful to confirm the
diagnosis of inhalant allergy. However it can be of use in diagnosis of
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occupational allergy. Methacholine or histamine is widely used for nasal
challenge test. Both induce dose dependant increase in secretions
ROLE OF IMAGING
Computerized tomography is of limited use in the diagnosis of
allergic rhinitis. Computerized tomography is done:
• to rule out other conditions
• to exclude CRS
• to eliminate complications in rhinitis;
• in patients not responding to treatment and
• in patients with unilateral rhinitis
ASSESSMENT OF SEVERITY
PULMONARY FUNCTION TESTS
There is a strong relationship between asthma and allergic rhinitis
as they share a common pathophysiology and anatomy, this entity  has
been called the ‘‘unified airway disease’’. Pulmonary function tests
(PFT)   help  in  diagnosis  and  predict  severity.  They  can  be  used  to
monitor both disease progression and therapeutic response. Pulmonary
function tests  are used to obtain objective data. PFT include
32
(1) spirometry,  (2) assessment of lung volumes, (3) body
plethysmography, (4) diffusion capacity and (5) flow-volume loops.
Spirometry is used to evaluate FVC and FEV1. The graphs can
indicate normal patterns or abnormal patterns of obstructive, restrictive,
or mixed lung disease. Spirometry alone cannot establish a diagnosis,
but it is used to assess and monitor disease and also to gauge response to
treatment.  Normal FEV1 is 80% of the FVC.  FEV1/FVC ratio is also
used.  Asthma is characterized by normal to decreased FVC, decreased
FEV1 and FEV1/FVC ratio. Restrctive lung disease is characterized by
a normal or increased FEV1/FVC ratio and a decrease in all lung
volumes. Lower  airway obstruction is assessed by FEV1.  A predicted
value of FEV1 between 70% and 85% is mild, while a value between
60% and 69% is considered as  moderate. Values between 50% to 59%
is moderately severe, between 35% and 49% is considered as  severe,
and less than 35% is very severe obstruction.
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VISUAL ANALOGUE SCALE
The joint task force on practice parameters proposed visual
analogue scale for the symptom severity assessment for allergic rhinitis.
7 point visual analog scale is used.
ASSESSING NASAL SYMPTOM SEVERITY
SNEEZING 1 2        3      4        5     6 7
NASAL RHINORRHEA
NASAL OBSTRUCTION
ITCHING
POST NASAL DRIP
ASSESSING NON NASAL  SYMPTOM SEVERITY
EYE SYMPTOMS 1 2       3      4       5       6 7
THROAT SYMPTOMS
EAR SYMPTOMS
COUGH
HEADACHE
MENTAL FUNCTION
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KEY
1. Occasional episodes
2. Mild but easily tolerable
3. moderate but symptoms are hard to tolerate and may interfere
with daily activities
4. severe symptoms such that patient cannot function all the time
QUALITY OF LIFE ASSESSMENT OF RHINITIS SEVERITY
                                          1 2            3         4       5           6 7
            Severely affected             Excellent
1. QOL is terribly affected in terms of sleep disturbance at night and
/impairment of work performance and/impairment of social
activities.
2. QOL is affected almost all the time.
3. QOL is affected often.
4. QOL is affected occasionally but it is tolerable.
5. QOL is hardly affected.
6. QOL is mildly affected.
7. Excellent quality of life.
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MANAGEMENT
PREVENTION: Allergen avoidance is mandatory
PHARMACOTHERAPY
Oral or intranasal of Second-generation antihistamines are used
for allergic rhinitis. Intranasal steroids are also used in allergic rhinitis.
Montelukast is used for seasonal allergic rhinitis in children more than 6
years. Topical cromones are modestly effective in allergic rhinitis.
Intranasal decongestants is also recommended. Intranasal ipratropium is
used for rhinorrhoea associated with allergic rhinitis. Despite optimal
pharmacotherapy some patients with moderate/severe allergic rhinitis do
not become symptom free.
ALLERGEN SPECIFIC IMMUNOTHERAPY
Noon and Freeman introduced Allergen immunotherapy in 1911.
Immunotherapy involves the step-wise incremental injection of
increasing subcutaneous doses of allergen, in order to suppress
symptoms on subsequent re-exposure to that allergen. Immunotherapy,
given monthly for three to four years, has been shown to induce long-
term remission for at least three years following discontinuation of
treatment.  In children, immunotherapy reduces the risk of physician-
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diagnosed asthma at three to five years after commencing treatment and
prevents the onset of new allergen sensitivities in children. Studies
strongly suggest that immunotherapy is the only treatment that has the
potential to modify the course of allergic disease. Thus immunotherapy
favourably improves quality of life. Allergen-specific immunotherapy
can be administered by sublingual and subcutaneous routes. It is
effective in pollen and mite allergy. It alters the natural course of
allergic diseases. Subcutaneous immunotherapy provides symptomatic
improvement for many years even after completion of treatment. It
prevents sensitization to other allergens in future.
SUBCUTANEOUS IMMUNOTHERAPY
The optimal dose is the dose of allergen vaccine that gives a
clinically relevant effect in most of the patients without any adverse
effects. 5–20 micro grams is the optimal dose used clinically.
INDICATIONS
? Symptomatic on allergen exposure.
? Rhinitis and lower airway symptoms during peak allergen
exposure symptoms during pollen seasons.
? Patients with inadequate symptom control despite antihistamines
and topical steroids.
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? Patients with side effects to pharmacotherapy.
? To avoid long-term pharmacotherapy
CONTRAINDICATIONS
? Patients on ß-blockers
? Patients with any other immunologic disease
? Patients with poor compliance
? Starting immunotherapy during known pregnancy
Immunologic changes observed with immunotherapy treatment
Initially IgG1 increases; after treatment for 2 years with
immunotherapy, Reduction in IgG1 noted, Gradual increase in IgG4
Reduced neutrophils, esinophils, Decrease in antigen-specific IgE
and reduced  post  seasonal  increase in IgE, Decrease in IL 13,
Decrease in serum prolactin, Reduction in T cell proliferation, Increased
IL-10 production, Decrease in serum ECP, Decrease in urinary
leukotriene levels, Decrease in nasal tryptase and specific IgE.
IMMUNOTHERAPY
IgE
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ALGORITHM FOR IMMUNOTHERAPY
suspected allergic rhinitis, allergic asthma
?
detailed history, physical examination, laboratory tests.
?
Consider immunotherapy  when specific IgE antibodies are positive and
correlate with suspected triggers and patient exposure
?
Assess benefit/ risk/ costs of appropriate management options
-patient preference
-allergen avoidance
-pharmacotherapy
-severity of disease
-response to prior treatment
-immunotherapy
?
Consider immunotherapy for symptoms not controlled by medications
and allergen avoidance/ require high medication dose or long term use/
multiple medications
?
Informed consent/ counsel about duration of immunotherapy and onset
of efficacy
?
Identification of specific allergenic extracts
Starting dose- 1000 to 10,000 fold less than maintenance dose
Build up schedule- gradually increasing doses from 8 to 28 weeks every
1- 3 times a week
?
maintenance dose- 500 to 2000 allergy units/ 5 to 20 micro gram
every 2-4 weeks
?
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Patient should wait 30 mins in clinic after injection; well equipped to
manage any complications of immunotherapy
?
Follow up every 6- 12 weeks
Clinical response to immunotherapy based on symptoms and medication
use
?
Usual duration-3 to 5 years
Based on severity of disease, convenience of treatment, benefits
sustained from treatment- decide to continue or stop immunotherapy
SIDE EFFECTS OF IMMUNOTHERAPY
Severe systemic reactions occur only in less than 1 % of patients
receiving immunotherapy.
Grade I- Cutaneous- pruritis, urticarial.  URI- sneezing, rhinorrhea,
pruritis or itchy throat, cough, Conjuctival- pruritis, Nausea, headache
Grade II- Lower respiratory – cough, wheeze. GIT- cramps, diarrhea,
vomiting. Uterine cramps.
Grade III- Asthma not responding to bronchodilators. Laryngeal edema
with or without stridor. Cardiovascular.
Grade IV- Respiratory failure, loss of consciousness. Hypotension
Grade V- death
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MATERIALS AND METHODS
Cases of ALLERGIC RHINITIS coming to Upgraded Institute of
Otorhinolaryngology, Rajiv Gandhi Government General Hospital, who
satisfy the inclusion criteria that are studied during the year Oct 2011 –
OCt 2013. Study material consists of 30 cases.
INCLUSION CRITERIA :
? Age above 12 years
? Sex- both male and female
? Allergic rhinitis not responding to pharmacotherapy with positive
allergic skin tests with or without polyposis
EXCLUSION CRITERIA :
? Children less than 12 years
? Pregnancy.
? Extreme response to skin tests.
? Uncontrolled severe asthma
? Patients on beta blockers
? Other medical/ immunological disease
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A total of 30 patients  with symptoms suggestive of allergic rhinitis
were evaluated by visual analogue scale.
Following nasal symptoms are assessed for severity
Sneezing, Nasal Rhinorrhea, Nasal Obstruction, Itching, Post
nasal Drip.
Following non nasal symptoms are assessed for severity
Eye symptoms, Throat symptoms, Ear symptoms, Cough,
Headache, Mental function, Wheeze,
History of medications taken for allergic rhinitis was noted.
Hematological Investigations:
Complete hemogram- hemoglobin percentage, total count,
differential count(polymorphs, lymphocytes, eosinophils).
Absolute eosinophil count
Total IgE
Pulmonary Function Tests- FEV1 %
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SKIN TESTS
Intradermal skin tests was used. 0.02 ml of test allergen
introduced intradermally with mantoux syringe on the volar aspect of
forearm. Result is read at varying period and induration and erythema
measured against the control. An induration of 3 mm more than control
is considered as positive. Result is graded as +,++,+++ measured in mm.
Allergic skin tests is done for following allergens:
INHALANT ALLERGEN:
House Dust, Cotton Dust, Aspergillus, Pollen, Parthenium,
Cockroach.
MEAT PROTEINS:
Beef/ chicken/ crab/ egg/ mutton/ prawns/ fish
FRUITS AND VEGETABLES:
Tomato/ apple/ potato
PULSES:
Bengal gram/ black gram/ channaetc
MILK PROTEINS:
Milk/ butter/ cheese/ curd
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BUILD UP PHASE
Allergen extract is slowly increased from 0.05 ml to 0.5 ml of 1 in
1,00,000 dilution on weekly twice interval
DILUTIONS
DOSE 100000 10000 1000 100 50
0.05 ml 1 7 13 19 25
0.1 ml 2 8 14 20 26
0.2 ml 3 9 15 21 27
0.3 ml 4 10 16 22 28
0.4 ml 5 11 17 23 29
0.5 ml 6 12 18 24 30
Maintenance phase- 0.5 ml of 1 in 50 dilution of allergen is given at
monthly twice interval.
BOOSTER DOSE
months I II III IV V VI VII
FIRST 1 1 1 1 1 1 1
2 2 2 2 2 2 2
SECOND 3 3 3 3 3 3 3
4 4 4 4 4 4 4
THIRD 5 5 5 5 5 5 5
6 6 6 6 6 6 6
FOURTH 7 7 7 7 7 7 7
8 8 8 8 8 8 8
FIFTH 9 9 9 9 9 9 9
10 10 10 10 10 10 10
SIXTH 11 11 11 11 11 11 11
12 12 12 12 12 12 12
After one year of treatment, symptom severity is assessed. Absolute
eosinophil count, IgE and pulmonary function tests are measured. Skin
tests are done for six inhalant allergens. Reduction of other medicines
taken following initiation of immunotherapy was also studied.
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RESULTS AND ANALYSIS
SEX FREQUENCY PERCENT
Male 15 50.0
Female 15 50.0
Total 30 100.0
INDIVIDUAL SYMPTOM ANALYSIS
SNEEZE BEFORE AND AFTER TREATMENT
VAS-BT FREQUENCY PERCENT
Absent 1 3.3
5 2 6.7
7 27 90.0
Total 30 100.0
VAS – AT FREQUENCY PERCENT
Absent 20 66.7
3 9 30.0
7 1 3.3
Total 30 100.0
Sneezing was present in 96.7% of the subjects and reduced to
33.3% after immunotherapy.  Immunotherapy was effective in
completely relieving sneezing in 63.4%.
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RUNNING NOSE BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
  Absent 0 0 Absent 21 70.0
3 1 3.3 3 8 26.7
5 4 13.3 - - -
7 25 83.3 7 1 3.3
Total 30 100.0 Total 30 100.0
Running nose was present in all patients. On using
immunotherapy, 70% symptomatic relief is noted in rhinorrhea while
26.7% had reduction in symptoms.
NASAL OBSTRUCTION BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
Absent 18 60.0 Absent 27 90
3 4 13.3 3 2 6.7
5 6 20.0 - - -
7 2 6.7 7 1 3.3
Total 30 100.0 Total 30 100
Nasal obstruction which was present in 40% of patients and
reduced to 10% after immunotherapy.
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ITCHING BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
Absent 6 20.0 Absent 20 66.7
3 4 13.3 3 7 23.3
5 7 23.3 5 2 6.7
7 13 43.3 7 1 3.3
Total 30 100.0 TOTAL 30 100
Itching was present in 80% of patients and reduced to 33.3% after
immunotherapy.
POST NASAL DRIP BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
Absent 20 66.7 Absent 27 90
3 2 6.7 3 3 10.0
5 2 6.7 - - -
7 6 20.0 - - -
Total 30 100.0 Total 30 100
Post nasal drip was seen in 33.3% of patients and was reduced to
10% after immunotherapy
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WHEEZE BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
ABSENT 24 80.0 ABSENT 29 96.7
3 1 3.3 3 1 3.3
5 5 16.7 - - -
Total 30 100.0 Total 30 100.0
Wheeze was seen in 20% of patients and was reduced to 3.3%
after immunotherapy. 83.3% of patients with wheeze were relieved from
symptom.
EYE SYMPTOMS  BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
ABSENT 16 53.3 1 21 70
3 2 6.7 3 6 20
5 6 20.0 5 2 6.7
7 6 20.0 7 1 3.3
Total 30 100.0 Total 30 100.0
Irritation of eye was seen in 46.7% which was reduced to 30%
after immunotherapy.
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EAR SYMPTOMS BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
1 18 60.0 1 22 73.3
3 1 3.3 3 5 16.7
5 7 23.3 5 2 6.7
7 4 13.3 7 1 3.3
Total 30 100.0 TOTAL 30 100
Ear symptoms were seen in 40% of patients and reduced to 26.7%
after immunotherapy.
THROAT SYMPTOMS BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
1 20 66.7 1 24 80.0
- - - 3 3 10.0
5 6 20.0 5 2 6.7
7 4 13.3 7 1 3.3
Total 30 100.0 TOTAL 30 100
Throat symptoms were seen in 33.7% of patients which was
reduced to 20% after immunotherapy.
49
COUGH BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
1 25 83.3 1 29 96.7
3 1 3.3 3 1 3.3
5 3 10.0 - - -
7 1 3.3 - - -
Total 30 100.0 TOTAL 30 100
Cough was seen in 16.6% of patients and it was reduced to 3.3%
after immunotherapy
HEADACHE BEFORE AND AFTER TREATMENT
VAS-BT FRE % VAS - AT FRE %
1 21 70.0 1 25 83.3
3 3 10.0 3 5 16.7
5 5 16.7 - - -
7 1 3.3 - - -
Total 30 100.0 Total 30 100
Headache was seen in 30% of study group and was reduced to
16.7% after immunotherapy
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DESCRIPTIVE STATISTICS FOR NASAL SYMPTOMS
BEFORE AND AFTER IMMUNOTHERAPY
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SNEEZE 30 6.67 1.184 7 7 7
RUNNING
NOSE
30 6.6 0.968 7 7 7
OBSTRUCTIO
N
30 2.47 2.03 1 1 5
ITCHING 30 4.8 2.369 3 5 7
POST NASAL
DRIP
30 2.6 2.486 1 1 5
SNEEZE – AT 30 1.8 1.349 1 1 3
RUNNING
NOSE – AT
30 1.73 1.337 1 1 3
OBSTRUCTIO
N – AT
29 1.34 1.203 1 1 1
ITCHING – AT 30 1.93 1.552 1 1 3
POST NASAL
DRIP – AT
29 1.21 0.62 1 1 1
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WILCOXON SIGNED RANKS TEST TO COMPARE THE MEAN
NASAL SYMPTOMS BEFORE AND AFTER INTERVENTION
VARIABLE RANKS N MEAN
RANK
P-VALUE
SNEEZE - AT –
SNEEZE
Negative Ranks 28 14.50
<0.001
Positive Ranks 0 .00
RUNNING NOSE -
AT - RUNNING
NOSE
Negative Ranks 29 15.00
<0.001
Positive Ranks 0 .00
OBSTRUCTION - AT
– OBSTRUCTION
Negative Ranks 10 5.50
0.004
Positive Ranks 0 .00
ITCHING - AT –
ITCHING
Negative Ranks 23 12.00
<0.001
Positive Ranks 0 .00
POST NASAL DRIP -
AT - POST NASAL
DRIP
Negative Ranks 10 5.50
0.004
Positive Ranks 0 .00
Reduction of all nasal symptoms –sneeze, running nose, nasal
obstruction, itching, post nasal drip were statistically significant as seen
in the above table.
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DESCRIPTIVE STATISTICS
STATISTICS N MEAN STD
DEVIATION
NASAL
SYMPTOMS
MEAN
30 4.627 1.0657
NASAL
SYMPTOMS
MEAN  AT
30 1.627 1.0593
WILCOXON SIGNED RANKS TEST TO COMPARE THE MEAN
NASAL SYMPTOMS BEFORE AND AFTER INTERVENTION
VARIABLE RANKS N MEAN
RANK
P-VALUE
NASAL SYMPTOMS
(MEAN) – AT –
NASAL SYMPTOMS
(MEAN)
Negative Ranks 29 15.00
<0.001
Positive Ranks 0 .00
Reduction of nasal symptom mean score was statistically
significant after immunotherapy as seen in the above tables
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DESCRIPTIVE STATISTICS FOR NON NASAL SYMPTOMS
BEFORE AND AFTER IMMUNOTHERAPY
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WHEEZE 30 1.73 1.53 1 1 1
EYE 30 3.13 2.515 1 1 5
EAR 30 2.8 2.369 1 1 5
THROAT 30 2.6 2.372 1 1 5
COUGH 30 1.67 1.605 1 1 1
HEADACHE 30 2.07 1.799 1 1 3
WHEEZE –
AT
30 1.07 0.365 1 1 1
EYE – AT 30 1.87 1.548 1 1 3
EAR – AT 30 1.8 1.54 1 1 3
THROAT –
AT
30 1.67 1.516 1 1 1
COUGH –
AT
30 1.07 0.365 1 1 1
HEADACHE
– AT
30 1.33 0.758 1 1 1
54
WILCOXON SIGNED RANKS TEST TO COMPARE THE BEFORE
AND AFTER INTERVENTION
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WHEEZE - AT –
WHEEZE
Negative Ranks 6 3.50
0.023
Positive Ranks 0 .00
EYE - AT – EYE
Negative Ranks 13 7.00
0.001
Positive Ranks 0 .00
EAR - AT – EAR
Negative Ranks 11 6.00
0.002
Positive Ranks 0 .00
THROAT - AT –
THROAT
Negative Ranks 9 5.00
0.006
Positive Ranks 0 .00
COUGH - AT –
COUGH
Negative Ranks 5 3.00
0.041
Positive Ranks 0 .00
HEADACHE -
AT –
HEADACHE
Negative Ranks 9 5.00
0.004
Positive Ranks 0 .00
Reduction of wheeze was statistically significant as seen in the
above table.
Reduction of all non nasal symptoms –eye symptoms , ear
symptoms, throat symptom, cough, headache were statistically
significant as seen in the above table.
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DESCRIPTIVE STATISTICS FOR MEAN NON NASAL
SYMPTOMS BEFORE AND AFTER IMMUNOTHERAPY
STATISTICS N MEAN
STD
DEVIATION
NON NASAL
SYMPTOMS
MEAN
30 2.33 1.10
NON NASAL
SYMPTOMS
MEAN AT
30 1.47 0.73
WILCOXON SIGNED RANKS TEST TO COMPARE THE MEAN
NON NASAL SYMPTOMS BEFORE AND AFTER INTERVENTION
VARIABLE RANKS N MEAN
RANK
P-VALUE
Non Nasal
Symptoms Mean -
AT - Non Nasal
Symptoms Mean
Negative Ranks 23 12.00
<0.001
Positive Ranks 0 .00
Reduction of non nasal symptoms mean was statistically
significant after immunotherapy as seen in the above table
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DIAGNOSTIC NASAL ENDOSCOPY
DNE FREQUENCY PERCENT
ITH 27 90.0
Polyp 3 10.0
Total 30 100.0
POLYP was seen in 10% of patients. All these patients had no
recurrence after post FESS immunotherapy.
FAMILY HISTORY FREQUENCY PERCENT
Nil 20 66.7
Father 5 16.7
Mother 5 16.7
Total 30 100.0
33.4% people had family history.
ITH
90%
Polyp
10%
DNE
Nil
66%
Father
17%
Mother
17%
FAMILY HISTORY
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MEDICATIONS REQUIREMENTS BEFORE AND AFTER
TREATMENT
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1 16 53.3 2 3 10.0
2 12 40 3 11 36.7
3 2 6.7 4 10 33.3
5 6 20.0
Total 30 100 Total 30 100.0
Key
1. Not taken treatment
2. Occasionally taken antihistamines
3. Use of antihistamines regularly/ intermittently
4. Use of antihistamines daily.
5. Use of topical steroids and antihistamines.
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DESCRIPTIVE STATISTICS
STATISTICS N MEAN STD DEVIATION
Total score 30 3.376 0.831
Total score-
AT
30 1.539 0.654
WILCOXON SIGNED RANKS TEST
VARIABLE NO RANK MEAN P
Total score –
AT total
score
30 Negative
rank
15.50
<o.oo1
Positive rank .0
Reduction of medication requirement was statistically significant.
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DESCRIPTIVE STATISTICS FOR ALLERGENS
HOUSE DUST SENSITIVITY BEFORE AND AFTER TREATMENT
BT FRE % AT FRE %
Negative 4 13.3 Negative 13 43.3
1 6 20.0 1 11 36.7
2 13 43.3 2 6 20.9
3 6 20.0 - - -
4 1 3.3 - - -
Total 30 100.0 Total 30 100.0
86.6 % of patients sensitized with house dust allergen.34.6% of
them becomes negative 65.3% of them showed  reduction in sensitivity.
COTTON SENSITIVITY BEFORE AND AFTER TREATMENT
BT FRE % AT FRE %
Negative 3 10.0 Negative 14 46.7
1 7 23.3 1 16 53.3
2 16 53.3 - - -
3 4 13.3 - - -
Total 30 100.0 TOTAL 30 100
90% of study groups were sensitive to cotton dust.40% of them
becomes negative. 60% of them showed reduction in sensitivity
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ASPERGILLUS SENSITIVITY BEFORE AND AFTER
TREATMENT
BT FRE % AT FRE %
Negative 9 30.0 Negative 20 66.7
1 12 40.0 1 8 26.7
2 6 20.0 3 2 6.7
3 3 10.0 - - -
Total 30 100.0 Total 30 100.0
70% of study groups were sensitive to Aspergillus.52% becomes
negative. 48% showed reduction in sensitivity.
POLLEN SENSITIVITY BEFORE AND AFTER TREATMENT
BT FRE % AT FRE %
Negative 1 3.3 Negative 7 23.3
1 13 43.3 1 15 50.0
2 10 33.3 2 8 26.7
3 6 20.0 - - -
Total 30 100.0 Total 30 100.0
96.6% of patients showed pollen sensitivity.20% of them
becomes negative. 80% of them showed reduced sensitivity
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COCKROACH SENSITIVITY BEFORE AND AFTER TREATMENT
BT FRE % AT FRE %
Negative 4 13.3 Negative 5 16.7
1 3 10.0 1 15 50.0
2 14 46.7 2 10 33.3
3 9 30.0 - - -
Total 30 100.0 Total 30 100.0
86.7% of the study group had sensitivity to cockroach.3.8%
becomes negative. 96.2% of them showed reduction in sensitivity
PARTHENIUM SENSITIVITY BEFORE AND AFTER
TREATMENT
BT FRE % AT FRE %
Negative 1 3.3 Negative 5 16.7
1 1 3.3 1 18 60.0
2 19 63.3 2 5 16.7
3 8 26.7 3 2 6.7
4 1 3.3 Total 30 100.0
96.7% of the study groups had sensitivity to Parthenium.13.7% of
them becomes negative . 86.3% of them showed reduction in sensitivity.
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DESCRIPTIVE  STATISTICS FOR  ALLERGEN
STATISTICS N MEAN STD. DEVIATION
HOUSE DUST 30 1.8 1.031
COTTON 30 1.7 0.837
ASPER 30 1.1 0.96
POLLEN 30 1.7 0.837
COCKROACH 30 1.93 0.98
PARTHENIUM 30 2.23 0.728
DESCRIPTIVE STATISTICS  FOR  ALLERGEN  AFTER
IMMUNOTHERAPY
STATISTICS N MEAN STD. DEVIATION
HOUSE DUST 30 0.77 0.774
COTTON 30 0.53 0.507
ASPER 30 0.47 0.819
POLLEN 30 1.03 0.718
COCKROACH 30 1.17 0.699
PARTHENIUM 30 1.13 0.776
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WILCOXON SIGNED RANKS TEST
VARIABLE RANKS N MEAN
RANK
P-VALUE
HOUSE DUST
- AT - HOUSE
DUST
Negative Ranks 23 13.35
0.001
Positive Ranks 3 14.67
COTTON - AT –
COTTON
Negative Ranks 25 13.00
<0.001
Positive Ranks 0 .00
ASPER - AT -
ASPER
Negative Ranks 14 8.21
0.001
Positive Ranks 1 5.00
POLLEN - AT -
POLLEN
Negative Ranks 16 8.50
<0.001
Positive Ranks 0 .00
COCKROACH -
AT –
COCKROACH
Negative Ranks 16 10.06
0.001
Positive Ranks 2 5.00
PARTHENIUM
- AT –
PARTHENIUM
Negative Ranks 25 14.40
<0.001
Positive Ranks 2 9.00
Reduction in skin  sensitivity for all  allergen was statistically
significant. Response to house dust and aspergillus were better than
pollen.
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DESCRIPTIVE STATISTICS FOR AEC AND IGE
STATISTIC N MEAN STD DEVIATION
AEC 30 202.5 73.5
AEC-AT 30 138.6 33.988
IGE 30 547.8 74.1
IGE –AT 30 136.7 33.988
The mean value of AEC and IGE reduced after immunotherapy
WILCOXON SIGNED RANKS TEST TO COMPARE THE BEFORE
AND AFTER INTERVENTION
Variable Ranks N Mean
Rank
P-Value
AEC - AT -
AEC
Negative
Ranks 30 15.50
<0.001
Positive
Ranks 0 .00
IGE - AT - IGE
Negative
Ranks 29 15.45
<0.001PositiveRanks 1 17.00
Positive
Ranks 7 4.00
Reduction of absolute eosinophil count and IG E were statistically
significant as seen in the above table. IgE count was more than 200 in
15 cases after treatment only 2 patients had more than 200 IU.
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DESCRIPTIVE STATISTICS
STATISTICS N MEAN STD DEVIATION
FEV1%           30 80.563 7.086
FEV1% - AT           30 86.933 5.164
Mean value for FEV1% was increased from 80.56 to 86.933%
after immunotherapy.
WILCOXON SIGNED RANKS TEST
Variable Ranks N MEAN P VALUE
FEV1%-AT-
FEV1%
Negative ranks 0 00
<0.001
Positive ranks 30 15.50
Improvement in pulmonary function was statistically significant.
SIDE EFFECTS
AT FRE %
None 28 93.3
LOCAL REACTION 2 6.7
Total 30 100.0
Only -6.7 percent of study group had side effects –Local reaction
at the site of injection. No patients had severe systemic reaction
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QUALITY OF LIFE BEFORE AND AFTER TREATMENT
BT FRE % AT FRE %
1 1 3.3 5 8 26.7
2 14 46.7 6 13 43.3
3 10 33.3 7 9 30.0
4 5 16.7 - - -
Total 30 100.0 Total 30 100.0
DESCRIPTIVE STATISTICS
STATISTICS N MEAN STD
DEVIATION
Quality of life 30 2.630 0.809
Quality of life- AT 30 6.030 0.765
WILCOXON SIGNED RANKS TEST
Variable Ranks N mean P value
Quality of life-AT-
quality of life
Negative
ranks
0 .00
<0.001
Positive
ranks
30 15.50
Improvement in Quality of life was statistically significant.
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PERCENTAGE IMPROVEMENT
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% improvement in
Nasal Symptoms 30 64.9 18.6 52.2 72.1 76.2
% improvement in
Non-nasal
Symptoms
30 31.7 21.7 15.0 38.2 45.8
% improvement in
total score 30 54.1 15.8 47.3 58.2 64.6
% reduction in
House dust 26 65.4 45.0 50.0 66.7 100.0
% reduction in
Cotton 27 69.1 30.2 50.0 66.7 100.0
% reduction in
Asper 21 62.7 47.1 0.0 100.0 100.0
% reduction in
Pollen 29 37.9 40.1 0.0 33.3 66.7
% reduction in
Cockroach 26 38.5 35.5 0.0 41.7 66.7
% reduction in
Parthenium 29 47.7 36.4 41.7 50.0 66.7
% improvement in
Quality of life
30 148.9 78.6 93.8 141.7 200.0
Nasal symptoms have improved by 64.9%. Improvement in Nasal
symptoms is better than Non-Nasal symptoms.
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DISCUSSION
JOHNSTONE AND DUTTON7  (1968)-14 yr study in 173
children with bronchial asthma. After 4yrs of SCIT symptomatic
improvement was assessed.78% of rate of remission of asthma was
observed.
In my study 83.3% rate of remission of asthma was observed.
LOWELL AND FRANKLIN8 (1965)- Study in 24 adults with
rhinoconjunctivitis with a mixture of ragweed & multiple allergens
conducted over a period of 8 months. Study result showed significant
improvement in median symptom score.
In my study,median significant score showed improvement.
FRANKLIN &LOWELL14 (1967)- Study in 24 individuals with
allergic rhinitis with low dose & high dose mixture of ragweed extract
in multiple pollen allergens. Symptom scores were significantly reduced
with high dose ragweed extract than with the lower dose.
In  my study, I have used high dose of multiple pollen allergens.
Symptom score was significantly reduced.
GB PAJNO9 et al- Over a 6 yr follow up study, in 134 children
with asthma with or without rhinitis, HDM Specific immunotherapy
was given. New sensitization had occurred in 24.6% of children
administered with immunotherapy.
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In the study I have conducted, 13.3% new sensitization
recorded.4patients developed new sensitization after immunotherapy.
A.O.EIFAN10 et al- This study compared SCIT vs sublingual
immunotherapy in 43 individuals.  The median percentage improvement
in SCIT was
Total rhinitis symptom score -67%
Total asthma symptom score- 93%
Total symptom score- 81%.
In my study,
Total rhinitis symptom score -72.1%
Total asthma symptom score- 83.3%
Total symptom score- 58.2%.[both nasal non nasal symptoms]
VISNJAMILAVEC-PURETIC11 etal- In 87 allergic rhinitis
patients, retrospective study was conducted with SCIT.
There was a significant decrease in total IgE and specific IgE
Total IgE value of 441-1034 kU/l is decreased to 220-800 after 36
months of immunotherapy
In my study
The mean value of total Ig E547.8 is decreased to 136.7 after
immunotherapy.
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SUSMITHA J, VIJAYALAKSHMI20 et al conducted a study on
“combination of allergens in specific immunotherapy for IgE mediated
allergies”. It was noted that 58% showed no improvement in symptoms
due to incorrect combination of allergens.
THOMAS REINHOLD etal- study conducted on “Influence of
subcutaneous specific immunotherapy on drug costs in children
suffering from allergic asthma” .Decline in medication cost became
statistically significant  after 3yrs SCIT.
PFAAR O19 etal-2yr study  285 pts with mixed pollen
sensitization SCIT given.SMS assessed by VAS .Significant  reduction
in median SMS 5.7 compared with placebo .Quality of life were
significantly better for active group compared with placebo.
EWASWIEBOCKA etal study compared the efficacy of SCIT-
pre seasonal versus maintenance. In maintenance group, the intensity of
symptoms reduced in successive years.
ABRAMSON MJ17 etal in his Cochrane review reduced asthma
symptoms and medication requirements and bronchial hyperreactivity.
BLUMBERGA18 et al-  3 years of subcutaneous immunotherapy
showed improvement in skin reactivitiy and late asthmatic reactions
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JACOBSEN16 etal- In study group of allergic rhinitis patients,
only 25 % of SCIT group had asthma while 45 % of controls had
asthma.
PURELLO-D15 ambrosia conducted a study on 8000 allergic
adults,  out of which 27 % developed new sensitization after
immunotherapy.
SRIVASTAVA D13 etal-conducted study on patients with
coakroach allergy, significant improvement  was noted after one year of
subcutaneous therapy.
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CONCLUSION
Allergic rhinitis patients may progress to rhinosinusitis, sinonasal
polyposis and asthma.. Immunotherapy is the only treatment that has
potential to modify the course of allergic disease.
? My study has revealed subcutaneous immunotherapy for patients
with allergic rhinitis with or without polyposis reduces nasal and
non nasal symptoms significantly
? There is better improvement in nasal symptoms compared to non
nasal symptoms.
? Subcutaneous immunotherapy reduces medication requirement.
? Skin sensitivity reactions have reduced.
? Patients showed significant symptomatic improvement even when
skin sensitivity reactions were present.
?  Immunotherapy lowers total IgE and absolute eosinophil count.
?  Immunotherapy improves quality of life.
? Immunotherapy increases predicted value of FEV 1, thus reduces
the incidence of development of asthma in allergic rhinitis.
? In my study I would like to conclude that simultaneous
administration of different unrelated allergens in adequate dosage
and duration of treatment is the most effective.
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ABBREVIATIONS
AEC - Absolute Eosinophil Count
ARIA- Allergic Rhinitis and its Impact on Asthma
AT - After Treatment
BT- Before Treatment
DNE- Diagnostic Nasal Endoscopy
FEV1% - predicted value of Forced Expiratory Volume in 1 second
FRE- Frequency
IgE - Immunoglobulin E
ITH- Inferior Turbinate Hypertrophy
QOL- Quality of life.
SAPALDIA- Swiss study on Air Pollution And Lung Disease In adult
VAS- Visual Analogue Scale
Absolute eosinophil count.
Total IgE.
Pulmonary Function Tests- FEV1 %.
SKIN TESTS:
House Dust.
Cotton Dust.
Aspergillus.
Pollen.
Parthenium.
Cockroach.
DIAGNOSTIC NASAL ENDOSCOPY.
PROFORMA
Name Age Sex:
OP No. Occupation:
PERSONAL DATA:
1. Smoking :
2. Drug Allergy :
3. Asthma :
4. DM/HT :
FAMILY HISTORY:
Allergy/Asthma/ Eczema
SYMPTOMS:
Sneezing, Nasal Rhinorrhea, Nasal Obstruction, Itching, Post nasal
Drip,Eye symptoms, Wheeze Throat symptoms, Ear symptoms, Cough,
Headache, Mental function.
HISTORY OF MEDICATIONS:
HEMATOLOGICAL INVESTIGATIONS:
Complete hemogram- hemoglobin percentage, total count,
differential count(polymorphs, lymphocytes, eosinophils).
CONSENT FORM
STUDY TITLE : A STUDY ON “EFFECT OF
IMMUNOTHERAPY ON ALLERGIC RHINITIS”
I …………………………………………… hereby give consent to
participate in the study conducted by Dr.S. SHENBAGAVALLI, Post
Graduate in Upgraded Institute of Otorhinolaryngology, Madras Medical
College & Rajiv Gandhi Govt. General Hospital, Chennai and to use my
personal clinical data and result of investigation for the purpose of
analysis and to study the nature of disease. I also give consent for further
investigations.
Signature  / Thumb impression Place Date
of the patient / relative
Patient Name and Address
Signature of the Investigator
Signature of the Guide
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1 2 25 Male 5 5 1 3 5 3.8 3 3 3 1 3 1 ITH 54 44 2 156 1199 80.2 1 1 1 2 3 2 4 Father 2 1 1 1 1 1 1 1 1 1 1 1 1 146 138 83.2 Negative Negative 1 1 1 Negative 2 6
2 2 14 Male 7 7 3 3 1 4.2 1 1 1 1 5 1 ITH 56 41 2 216 283 96 Negative Negative Negative 1 2 3 2 Nil 2 1 1 1 1 1 1 1 1 1 1 1 1 58 48 1 78 240 97 2 Negative Negative 1 2 1 1 7
3 2 53 Male 7 7 5 7 1 5.4 1 1 5 1 1 1 ITH 63 36 1 221 178 82 3 2 1 1 2 3 3 Father 3 1 1 1 1 1 1 1 1 3 1 1 1 156 148 86 1 1 Negative 1 2 1 1 6
4 1 37 Male 7 7 1 5 1 4.2 5 5 5 1 1 5 ITH 54 44 2 166 1265 68.6 2 2 2 2 3 2 5 Nil 2 1 1 1 3 1 1.4 3 3 3 1 1 3 145 130 78.6 1 1 Negative 1 1 2 2 5
5 2 39 Female 7 7 1 7 7 5.8 5 7 7 7 1 1 ITH 67 31 2 498 182 62 2 2 3 2 2 2 5 Mother 2 3 3 1 5 3 3 1 5 5 5 1 1 67 31 2 186 120 75 Negative Negative 3 2 2 1 3 6
6 1 15 Female 7 7 1 1 1 3.4 5 1 1 1 1 1 ITH 65 33 2 158 765 72.4 3 2 1 3 3 2 4 Nil 1 1 1 1 1 1 1 1 1 1 1 1 1 130 153 78.8 1 1 Negative 2 1 1 2 5
7 2 23 Male 7 7 1 7 7 5.8 1 7 7 7 1 1 ITH 63 36 1 168 258 80.4 Negative Negative Negative 2 2 2 2 Nil 4 1 1 1 1 1 1 1 1 1 1 1 1 146 172 90.3 Negative Negative Negative Negative Negative 1 1 7
8 2 33 Male 1 7 1 1 1 2.2 5 1 1 1 7 1 ITH 63 35 1 159 176 72.3 Negative 2 1 Negative Negative 2 3 Father 4 1 1 1 1 1 1 1 1 1 1 1 1 148 166 80.2 Negative 1 Negative Negative Negative 1 1 6
9 1 25 Female 7 7 1 7 7 5.8 1 7 7 7 1 1 ITH 62 34 2 162 180 83 2 2 1 3 2 2 4 Nil 3 1 1 1 1 1 1 1 7 7 7 1 1 154 148 87.5 1 1 1 2 2 1 1 6
10 1 17 Female 7 3 1 3 3 3.4 1 1 1 1 1 1 ITH 52 36 2 165 132 85 2 1 1 1 1 Negative 4 Nil 3 1 1 1 1 1 1 1 1 1 1 1 1 140 82 90.5 1 Negative Negative Negative 1 Negative 2 7
11 1 24 Female 7 7 3 1 1 3.8 1 3 1 1 1 3 ITH 56 42 2 169 611 80.5 1 1 2 1 Negative 2 3 Nil 3 1 1 1 1 1 1 1 1 1 1 1 1 145 153 89.9 Negative Negative 1 1 Negative 1 1 6
12 3 30 Male 7 7 3 7 3 5.4 5 1 1 1 1 1 ITH 70 28 2 134 3641 79 1 2 3 3 1 3 4 PALATAL ULCERFather 2 3 3 3 3 1 2.6 1 1 1 1 1 1 53 46 1 78 83 85.2 2 1 1 2 1 2 2 6
13 2 44 Female 7 7 1 5 1 4.2 1 5 5 1 1 5 Polyp 59 39 2 176 172 81 3 3 1 1 Negative 2 2 Nil 4 1 1 1 1 1 1 1 3 1 1 1 3 0 158 153 86.7 1 1 Negative Negative 1 Negative 1 PAIN 7
14 2 24 Female 7 7 5 7 5 6.2 1 5 1 5 1 5 ITH 59 39 2 182 80 79 3 3 Negative 3 3 3 3 Nil 3 1 1 1 1 1 1 1 1 1 1 1 3 138 72 88.8 1 1 Negative 1 2 2 1 6
15 3 26 Male 7 7 1 7 1 4.6 1 7 5 5 1 3 Polyp 62 36 1 316 1420 80.7 2 2 2 2 3 2 4 Mother 3 3 3 1 3 1 2.2 1 3 3 1 1 1 58 108 87.9 2 1 Negative 1 1 3 2 6
16 2 19 Male 7 5 1 5 1 3.8 1 1 1 1 1 1 ITH 58 40 2 178 174 88 3 3 Negative 3 3 3 3 Nil 2 3 1 1 1 1 1.4 1 1 1 1 1 1 165 86 94.5 1 1 Negative 1 2 1 1 5
17 2 26 Male 7 7 5 5 1 5 1 5 1 1 1 1 ITH 60 38 2 166 210 87.9 1 1 Negative 1 2 2 3 Nil 2 1 1 1 1 1 1 1 1 1 1 1 1 156 180 94.6 Negative Negative Negative 1 1 1 1 7
18 1 35 Male 7 7 7 7 1 5.8 1 1 1 1 1 1 Polyp 60 38 2 166 210 81.6 1 1 Negative 1 2 2 3 Nil 3 7 7 7 7 1 5.8 1 1 1 1 1 1 156 180 86.8 Negative Negative Negative 1 1 1 1 6
19 1 56 Male 7 5 1 1 1 3 1 1 5 1 5 1 ITH 56 42 2 196 153 83.7 1 1 Negative 1 2 2 4 Mother 2 1 1 1 1 1 1 1 1 3 1 3 1 185 97 88.4 Negative 1 1 Negative Negative Negative 1 6
20 1 29 Female 5 5 5 5 1 4.2 1 1 1 5 1 7 ITH 55 43 2 165 132 80.4 2 2 2 2 2 2 5 Nil 2 1 1 1 1 1 1 1 1 1 3 1 1 156 130 86.8 Negative Negative Negative 2 1 1 2 7
21 2 52 Female 7 7 1 7 7 5.8 1 1 1 1 1 1 ITH 58 40 2 192 97 84.7 2 2 Negative 1 2 3 3 Nil 4 1 1 1 1 1 1 1 1 1 1 1 1 142 72 89.8 Negative Negative Negative 1 Negative 2 2 7
22 1 18 Female 7 7 7 7 7 7 1 1 1 1 1 1 ITH 54 44 2 157 1106 83 2 2 2 3 3 3 5 Father 2 1 1 1 3 3 1.8 1 1 1 1 1 1 146 153 88 Negative Negative Negative 1 2 1 2 5
23 1 45 Female 7 7 5 1 1 4.2 1 5 1 1 1 5 ITH 60 38 2 185 218 85.3 4 2 1 2 3 4 4 Nil 3 1 1 1 1 1 1 1 3 1 1 1 3 172 145 89.6 2 1 1 2 1 2 1 6
24 1 19 Male 7 7 5 1 1 4.2 1 1 1 5 1 1 ITH 64 37 2 167 172 80.5 2 2 1 2 2 2 3 Nil 3 3 3 3 1 1 2.2 1 1 1 3 1 1 156 146 88.2 1 1 1 2 2 1 1 5
25 1 29 Female 7 7 1 7 1 4.6 1 1 1 5 1 1 ITH 60 44 2 178 152 84.5 2 1 1 1 1 1 4 Mother 2 3 3 1 3 1 2.2 1 1 1 3 1 1 156 106 88.9 1 1 1 1 1 1 2 5
26 2 15 Female 7 7 1 5 1 4.2 1 1 1 1 1 1 ITH 58 40 1 185 154 85 2 2 1 1 2 2 3 Nil 4 3 3 3 1 3 1 1 1 1 1 1 132 134 89 Negative Negative Negative Negative 1 1 1 7
27 2 26 Male 7 7 3 3 1 4.2 1 1 1 1 5 1 ITH 56 41 2 216 203 83.2 Negative Negative Negative 1 2 3 5 Nil 2 1 1 1 1 1 1 1 1 1 1 1 1 78 263 87.9 2 Negative Negative 1 2 1 2 7
28 3 24 Male 7 7 1 7 1 4.6 1 7 5 5 1 3 ITH 62 36 1 316 1420 81.4 2 2 2 2 3 2 3 Nil 3 3 3 1 3 1 2.2 1 3 3 1 1 1 58 108 85.9 2 1 Negative 1 1 3 1 5
29 2 18 Female 7 7 1 5 1 4.2 1 5 5 1 1 5 ITH 59 39 2 246 172 83.6 3 3 1 1 Negative 2 4 Mother 2 1 1 1 1 1 1 1 3 1 1 1 3 158 153 89 1 1 Negative Negative 1 Negative 2 PAIN 6
30 2 26 Female 7 7 1 7 7 5.8 1 7 7 7 1 1 ITH 67 31 2 316 1320 62 2 2 3 2 2 2 5 Nil 2 3 3 1 5 3 3 1 5 5 5 1 1 136 82 35.00% 75 Negative Negative 3 2 2 1 3 5
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